Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (NASDAQ:CRSP) reported its Q2 2025 financial results and business updates, highlighting significant progress across its commercial and clinical programs. The company's flagship product CASGEVY® has achieved its target of activating 75 authorized treatment centers globally, with ~115 patients completing cell collection and 29 receiving infusions.

Key clinical developments include CTX310™ showing promising preliminary data with up to 82% reduction in triglycerides and 86% in LDL, and ongoing trials for CTX112™ and CTX131™ in oncology and autoimmune diseases. The company maintains a strong financial position with $1.7 billion in cash and equivalents, despite reporting a net loss of $208.5 million for Q2 2025.

CRISPR Therapeutics (NASDAQ: CRSP) has been named to TIME's 100 Most Influential Companies list for 2025 in the Pioneers category. The recognition highlights the company's groundbreaking work in gene editing and its expansion beyond treating sickle cell disease and beta thalassemia into cardiovascular and autoimmune diseases.

The selection process involved TIME editors evaluating companies based on impact, innovation, ambition, and success, with input from global contributors, correspondents, and external experts. CEO Samarth Kulkarni emphasized the company's mission to transform medicine through science and innovation, viewing the recognition as validation of their team's dedication to advancing genetic medicine.

CRISPR Therapeutics (NASDAQ: CRSP) has reported positive additional Phase 1 data for its cardiovascular drug candidate CTX310, targeting ANGPTL3. The trial demonstrated impressive dose-dependent reductions of up to 82% in triglycerides and 86% in LDL, with a well-tolerated safety profile.

The company plans to present complete Phase 1 data for CTX310 in H2 2025. Additionally, CRISPR provided updates on two other cardiovascular programs: CTX320 targeting LPA gene, with data now expected in H1 2026, and CTX340 for refractory hypertension, which is advancing toward IND/CTA filings.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in June 2025. The company's senior management will present at William Blair's 45th Annual Growth Stock Conference on June 3 at 11:20 a.m. CT and at the Goldman Sachs' 46th Annual Global Healthcare Conference on June 9 at 3:20 p.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.

CRISPR Therapeutics and Sirius Therapeutics have announced a strategic partnership to develop siRNA therapies, with a primary focus on SRSD107, a Factor XI siRNA therapy for thromboembolic disorders. The collaboration involves a $95 million upfront payment from CRISPR ($25M cash + $70M equity). Phase 1 trials of SRSD107 showed promising results with >93% reduction in FXI activity and sustained efficacy up to 6 months post-dosing. The partnership includes a 50-50 cost and profit-sharing structure for SRSD107, with CRISPR leading U.S. commercialization and Sirius handling Greater China. Additionally, CRISPR gains rights to license two more siRNA programs. SRSD107 targets various conditions including atrial fibrillation, VTE, and cancer-associated thrombosis, offering potential advantages like lower bleeding risk and infrequent dosing. A Phase 2 trial is being initiated for VTE prevention in knee arthroplasty patients.

CRISPR Therapeutics (NASDAQ: CRSP) reported positive Q1 2025 results and breakthrough data from CTX310™'s Phase 1 trial. The trial demonstrated significant reductions in triglycerides (up to 82%) and LDL (up to 81%) with a well-tolerated safety profile. The company's flagship product CASGEVY® continues to expand globally with over 65 authorized treatment centers and 90+ patients having cells collected. Financial highlights include a strong cash position of $1.86 billion, though the company reported a net loss of $136.0 million. R&D expenses decreased to $72.5 million from $76.2 million YoY. The company's pipeline shows progress with ongoing trials for CTX320™, CTX112™, and CTX131™, with updates expected throughout 2025. CASGEVY® has secured reimbursement agreements in multiple regions and expects commercial production in Portsmouth, NH in H2 2025.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.

The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.

CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.

Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.